StockData
Seres Therapeutics, Inc. logo

Seres Therapeutics, Inc. (MCRB) stock

MCRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$1.41+0.00 (0.00%)

Close on Nov 17, 2026Market cap $14.02MP/E –Yield –

Seres Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Seres Therapeutics's price to sales ratio was 7.8× on Nov 11, 2026, against 449.2× a year earlier. Over the last 5 years it ranged from 0.9× to 449.2×, with a median of 50.9×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20267.8×−363.7
2025Dec 31, 2025371.6×+39.2
2024Oct 31, 2024332.4×+331.0
2023Dec 29, 20231.4×−50.7
2022Dec 30, 202252.1×+47.2
2021Dec 31, 20214.9×−91.1
2020Dec 31, 202096.0×+89.6
2019Dec 31, 20196.4×−2.5
2018Dec 31, 20188.9×−3.9
2017Dec 29, 201712.8×−8.5
2016Dec 30, 201621.3×–

More Seres Therapeutics figures

See a number that looks wrong?